Literature DB >> 23543347

Is there an association between Ro52/TRIM21 antibodies and rheumatoid factor in systemic sclerosis?

Sonal Mehra1, Marie Hudson, Michael Mahler, Murray Baron, Marvin Fritzler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23543347     DOI： 10.1007/s00296-013-2728-x

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


× No keyword cloud information.
  10 in total

1.  Anti-Ro52 antibody testing influences the classification and clinical characterisation of primary Sjögren's syndrome.

Authors:  Soledad Retamozo; Miriam Akasbi; Pilar Brito-Zerón; Xavier Bosch; Albert Bove; Marta Perez-de-Lis; Iratxe Jimenez; Maria-Jose Soto-Cardenas; Miriam Gandia; Candido Diaz-Lagares; Odette Viñas; Antoni Siso; Roberto Perez-Alvarez; Jordi Yague; Manuel Ramos-Casals
Journal:  Clin Exp Rheumatol       Date:  2012-10-17       Impact factor: 4.473

2.  Diagnostic utility of anti-Ro52 detection in systemic autoimmunity.

Authors:  Manish Dugar; Sally Cox; Vidya Limaye; Tom Paul Gordon; Peter John Roberts-Thomson
Journal:  Postgrad Med J       Date:  2010-02       Impact factor: 2.401

3.  Clinical and serological hallmarks of systemic sclerosis overlap syndromes.

Authors:  Angela Pakozdi; Svetlana Nihtyanova; Pia Moinzadeh; Voon H Ong; Carol M Black; Christopher P Denton
Journal:  J Rheumatol       Date:  2011-08-15       Impact factor: 4.666

4.  Rheumatoid factor isotypes and anti-agalactosyl IgG antibodies in systemic sclerosis.

Authors:  Y Mimura; H Ihn; M Jinnin; Y Asano; K Yamane; N Yazawa; K Tamaki
Journal:  Br J Dermatol       Date:  2004-10       Impact factor: 9.302

5.  Usefulness of anti-cyclic citrullinated peptide antibody and rheumatoid factor to detect rheumatoid arthritis in patients with systemic sclerosis.

Authors:  Ikuko Ueda-Hayakawa; Minoru Hasegawa; Sayako Kumada; Chihiro Tanaka; Kazuhiro Komura; Yasuhito Hamaguchi; Kazuhiko Takehara; Manabu Fujimoto
Journal:  Rheumatology (Oxford)       Date:  2010-07-27       Impact factor: 7.580

6.  Clinical and laboratory features of scleroderma patients developing skeletal myopathy.

Authors:  Yoshihiro Mimura; Hironobu Ihn; Masatoshi Jinnin; Yoshihide Asano; Kenichi Yamane; Kunihiko Tamaki
Journal:  Clin Rheumatol       Date:  2004-08-20       Impact factor: 2.980

7.  Anti-Ro52 reactivity is an independent and additional serum marker in connective tissue disease.

Authors:  I Peene; L Meheus; S De Keyser; R Humbel; E M Veys; F De Keyser
Journal:  Ann Rheum Dis       Date:  2002-10       Impact factor: 19.103

8.  Ro52 functionally interacts with IgG1 and regulates its quality control via the ERAD system.

Authors:  Mutsumi Takahata; Miyuki Bohgaki; Tadasuke Tsukiyama; Takeshi Kondo; Masahiro Asaka; Shigetsugu Hatakeyama
Journal:  Mol Immunol       Date:  2007-11-26       Impact factor: 4.407

Review 9.  Latest update on the Ro/SS-A autoantibody system.

Authors:  J Schulte-Pelkum; M Fritzler; M Mahler
Journal:  Autoimmun Rev       Date:  2009-02-12       Impact factor: 9.754

10.  Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis.

Authors:  Marie Hudson; Janet Pope; Michael Mahler; Solène Tatibouet; Russell Steele; Murray Baron; Marvin J Fritzler
Journal:  Arthritis Res Ther       Date:  2012-03-06       Impact factor: 5.156
  10 in total
  2 in total

Review 1.  A review of the role and clinical utility of anti-Ro52/TRIM21 in systemic autoimmunity.

Authors:  Adrian Y S Lee
Journal:  Rheumatol Int       Date:  2017-04-17       Impact factor: 2.631

2.  Uniphasic Blanching of the Fingers, Abnormal Capillaroscopy in Nonsymptomatic Digits, and Autoantibodies: Expanding Options to Increase the Level of Suspicion of Connective Tissue Diseases beyond the Classification of Raynaud's Phenomenon.

Authors:  Francesca Ingegnoli; Roberta Gualtierotti; Annalisa Orenti; Tommaso Schioppo; Giovanni Marfia; Rolando Campanella; Claudio Mastaglio; Pier Luigi Meroni; Patrizia Boracchi
Journal:  J Immunol Res       Date:  2015-05-17       Impact factor: 4.818
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.